Mettl3 promotes oxLDL-mediated inflammation through activating STAT1 signaling

Zhenwei Li  
Ningbo Hospital of Zhejiang University

Qingqing Xu  
Ningbo Hospital of Zhejiang University

Ning Huangfu  
Ningbo Hospital of Zhejiang University

Xiaomin Chen (chxmin@hotmail.com)  
Ningbo Hospital of Zhejiang University  https://orcid.org/0000-0003-1498-0452

Jianhua Zhu  
Zhejiang University School of Medicine

Research Article

Keywords: Atherosclerosis, Inflammation, Methyltransferase-Like Protein 3, N6-methyladenosine, Signal transducer and activator of transcription 1

DOI: https://doi.org/10.21203/rs.3.rs-327389/v1

License: ☑️ ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Atherosclerosis (AS) is the main cause of cerebrovascular diseases, and macrophages act important roles during the AS pathological process through regulating inflammation. Modification of the novel N(6)-methyladenine (m6A) RNA is reported to be associated with atherosclerosis, but its role in AS is largely unknown. The aim of this study was to investigate the role and mechanism of m6A modification in oxidised low-density lipoprotein (oxLDL) triggered inflammation in macrophages during AS. Dot blot, Immunoprecipitation, western blot, Rip and Chip experiments were used in our study. We find oxLDL stimulation significantly promotes m6A modification level of mRNA in macrophages and knockdown of Methyltransferase-Like Protein 3 (Mettl3) inhibits oxLDL-induced m6A modification and inflammatory response. Mettl3 promotes oxLDL-induced inflammatory response in macrophages through regulating m6A modification of Signal transducer and activator of transcription 1 (STAT1) mRNA, thereby affecting STAT1 expression and activation. Moreover, oxLDL stimulation obviously enhances Mettl3 interacting with STAT1 protein to promote STAT1 transcriptional regulation of inflammatory factor expression in macrophages, which was also demonstrated in the monocytes from patients with angiographically proven coronary artery disease. These results indicate that Mettl3 promotes inflammatory responses through interacting with STAT1 protein and mRNA in macrophages, suggesting that Mettl3 may be as a potential target for the clinical treatment of atherosclerosis.

1. Introduction

Atherosclerosis (AS), the major cause of cardiovascular diseases with its main complications, in particular stroke and myocardial infarction, is a chronic inflammatory disease with lipid accumulation and vascular injury [1]. Owing to more and more aging population and obesity prevalence, the occurrence rate of atherosclerotic disorders is expected to rise over the next decade, and the death number of patient with cardiovascular diseases is expected to over 23.6 million by 2030 [2, 3]. Although significant strides have been made in understanding the underlying mechanism of AS development and treating cardiovascular diseases [4, 5], safe and effective drugs for preventing and treating AS are still lack. Thus, deeply and fully elucidating the pathological mechanisms of AS is essential for finding novel drugs for AS.

Nowadays, AS is considered as a chronic inflammatory disease of the arterial wall characterized by lipid accumulation, cell necrosis and local inflammation [6]. Macrophages, the major immune cell population in atherosclerotic lesions, play important roles during AS development, from lesion initiation to plaque rupture [6, 7]. In plaque microenvironment, low-density lipoprotein is not only phagocytized by macrophages to induce the formation of foam cells, but also stimulates macrophages to release inflammatory factors such as interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) [8-10]. More recent studies reveal that signal transducer and activator of transcription 1 (STAT1) acts crucial roles in the pathology of AS through promoting expressions of several pro-inflammatory and pro-atherogenic mediators in macrophages, and is considered as a novel therapeutical target for AS[11], Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease. Thus,
understanding macrophage inflammation during AS appears as a prerequisite to develop novel therapeutic strategies for AS.

N6-methyladenosine (m6A) is the most abundant internal modification of RNA in eukaryotic cells, and is proved to regulate multiple aspects of RNA metabolism, including RNA processing, nuclear export, RNA translation, and RNA decay [12,13]. m6A modification is marked by "writers", including Methyltransferase-Like Protein 3 (Mettl3), Mettl14 and the associated protein Wilms Tumor 1 Associated Protein (WTAP), and is removed by "erasers", such as fat mass and obesity-associated protein (FTO) and AlkB Homolog 5 (ALKBH5) [14-16]. m6A modified RNA is recognized by “readers” to regulate gene expression [17,18]. Recent study finds that m6A modification levels of RNA are differentially regulated in atherosclerotic lesions [19]. Besides, Mettl14 is proved to promote endothelial inflammation and AS development [20], suggesting that RNA m6A modification is associated with AS development. However, whether RNA m6A modification is involved in macrophage inflammation during AS is still unknown.

In this study, we examined the m6A modification level of mRNA in oxLDL-stimulated macrophages, and the expressions of m6A "writers". We found that oxLDL stimulation significantly promoted m6A modification level of mRNA and Mettl3 expression in macrophages, and knockdown of Mettl3 inhibitd oxLDL-induced m6A modification and inflammatory response. In mechanism, Mettl3 enhances oxLDL-triggered inflammation through promoting STAT1 expression in a m6A-dependent manner, and Mettl3 interacts with STAT1 to promote STAT1 transcriptional regulation of inflammatory factor expression in RAW264.7 macrophages. In addition, higher m6A modification level and more Mettl3 protein and inflammatory factor expressions exist in monocytes from patients with angiographically proven coronary artery disease, compared to healthy donors. Overall, our study suggests that Mettl3 may be as a potential target for the clinical treatment of atherosclerosis.

2. Materials And Methods

2.1 Cell culture and treatment

RAW264.7 macrophage cells were purchased from the American Type Culture Collection (ATCC, USA) and grown in Dulbecco’s Modified Eagle's Medium (DMEM) (Sigma, USA) containing 10% fetal bovine serum (FBS) and antibiotics (100 U/mL penicillin A and streptomycin, respectively) at atmosphere of 5% CO2 in a 37 °C humidified incubator. Cells at 80% confluence were stimulated with 40 μg/mL ox-LDL (Sigma, USA) for 24 h.

2.2 Blood Sample Collections

In all subjects, blood samples were collected in the morning under a fasting state. Human MNCs were isolated from peripheral blood from 16 patients with angiographically proven coronary artery disease (CAD) and 8 healthy donors from Ningbo First Hospital. The study was approved by the research ethics review committee of Ningbo First Hospital, and subjects gave written informed consent before entering the study. Human monocytes were isolated from the peripheral blood by density gradient centrifugation
with Histopaque-1077 (1.077 g/mL, Sigma, USA). The monocytes were cultured in RPMI1640 medium with 10% FBS at atmosphere of 5% CO2 in a 37 °C humidified incubator.

### 2.3 Total RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR)

After treatment, total RNA of RAW264.7 macrophage cells was extracted using the Trizol reagent (Invitrogen, USA), and then reverse-transcribed into cDNA using the PrimeScript RT reagent Kit (TaKaRa, Japan). qRT-PCR was performed using SYBR-green PCR Master Mix in a Fast Real-time PCR 7500 System (Applied Biosystems). The sequences of RT-PCR primer were as following: Mettl3 (forward: 5′-CTGGGCACTTTGATTAAGGAA-3′; reverse: 5′-TGAGAGGTGGTGTAGCAACTT-3′); Mettl14 (forward: 5′-GAGCTGAGAGTGCGGATAGC-3′; reverse: 5′-GCAGATGTATCATAGGAAGCCC-3′); Wtap (forward: 5′-ATGGCAGGGATGTTAATTC-3′; reverse: 5′-ATGGCAACGGGATGAGTTAATTC-3′); IL-6 (forward: 5′-CTGCAAGAGACCTTTCCATCCAG-3′; reverse: 5′-AGTGTTAGACAGGTCTGTTG-3′); TNF-α (forward: 5′-CAGGCGGTGCTATCTC-3′; reverse: 5′-CGATCACCCTCGTAGTAC-3′); STAT1 (forward: 5′-TCACAGTGGTTCGAGCTTC-3′; reverse: 5′-CGAGACATCATAGGCAGCGTG-3′); oxidized low density lipoprotein (lectin-like) receptor 1 (LOX-1) (forward: 5′-CAAGATGAAGCCTGCGAATGA-3′; reverse: 5′-ACCTGGCGTAATTGTGTCCAC-3′); GAPDH (forward: 5′-TGGATTGGACGCATTGGTC-3′; reverse: 5′-TTTGCACTGGTACGTGGTGAT-3′). GAPDH was used as the internal control of the mRNA. Fold changes of target mRNA normalized to a control sample was calculated using the the \( 2^{-\Delta\Delta Ct} \) method.

### 2.4 Western blot

After treatment, total cellular proteins were lysed by RIPA buffer, harvested and then quantified by bicinchoninic acid (BCA) analysis (Beyotime, China). Protein extractions were separated by 10% SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, USA). After the incubation with primary antibodies, including anti-Mettl3 antibody (1:1000, Abcam, USA), anti-Mettl14 antibody (1:1000, Abcam, USA), anti-WTAP antibody (1:1000, Abcam, USA), anti-flag antibody (1:1000, Abcam, USA), anti-phosphorylated p38 antibody (p-p38, 1:1000, Abcam, USA), anti-p38 antibody (1:1000, Proteintech, China), anti-phosphorylated JNK antibody (p-JNK, 1:1000, Abcam, USA), anti-JNK antibody (1:1000, Proteintech, China), anti-phosphorylated p65 antibody (p-p65, 1:1000, Abcam, USA), anti-p65 antibody (1:1000, Proteintech, China), anti-phosphorylated STAT1 antibody (p-STAT1, 1:1000, Abcam, USA), anti-STAT1 antibody (1:1000, Proteintech, China), anti-phosphorylated STAT3 antibody (p-STAT3, 1:1000, Abcam, USA), anti-STAT3 antibody (1:1000, Proteintech, China), anti-LOX-1 antibody (1:1000, Proteintech, China), anti-FTO antibody (1:1000, Proteintech, China), anti-ALKBH5 antibody (1:1000, Proteintech, China), anti-RBM15 antibody (1:1000, Proteintech, China), anti-YTHDF1 antibody (1:1000, Proteintech, China), anti-YTHDF2 antibody (1:1000, Proteintech, China), anti-YTHDF3 antibody (1:1000, Proteintech, China), anti-IGF2BP1 antibody (1:1000, Proteintech, China), anti-IGF2BP2 antibody (1:1000, Proteintech, China), anti-IGF2BP3 antibody (1:1000, Proteintech, China), anti-EIF3A antibody (1:1000, Proteintech, China), anti-YTHDC1 antibody (1:1000, Proteintech, China), anti-YTHDC2 antibody (1:1000, Proteintech, China), and anti-GAPDH antibody (1:1000, Proteintech, China), the membranes were then incubated with peroxidase (HRP)-conjugated secondary antibody. After washes with PBS, protein bands
were detected using a chemiluminescence system (Bio-Rad, USA) and analyzed using Image Lab Software.

2.5 Cell transfection

Small interfering RNA (siRNA)-against Mettl3 (si-M3), siRNA-against STAT1 (si-ST1), and control siRNA were synthesized by GenePharma Company (Shanghai, China). A series of truncated mutants of Mettl3, including M3d (which has the mutation of C to S at the position of 314 amino acid, resulting in nearly abolishing the methyltransferase activity [21]), ΔN (which encompasses residues 259 to 580), and ΔNd (which has the mutation of C to S at the position of 314 amino acid in ΔN mutant) were synthesized by GenePharma Company (Shanghai, China), and then cloned into pCMV-Flag-vector. siRNAs or plasmids were transfected into Raw264.7 cells with lipofectamine 3000 (Invitrogen) under the guidance of operation instructions. Total RNA and protein were collected 48 h post-transfection for further experimental analyses.

2.6 RNA m6A dot blot assays

After treatment, RNA was extracted with mirVana RNA Isolation Kit (Thermo Scientific) and purified with Dynabeads mRNA Purification Kit (Thermo Scientific). mRNA (40 ng) was denatured by heating at 65 °C for 5 min, transferred onto a nitrocellulose membrane with a Bio-Dot apparatus (Bio-Rad, USA), UV cross-linked, blocked with 5% non-fat milk for 1 hour at room temperature, and incubated with anti-m6A antibody (1:350, Abcam, USA) at 4 °C overnight. After washes, the membrane was incubated with HRP-conjugated secondary antibody, treated with ECL substrate and developed using film.

2.7 Enzyme-linked immunosorbent assay (ELISA)

After treatments, the protein expressions of IL-6 or TNF-α in the cell culture supernatants were detected by the Mouse IL-6 ELISA Kit (Abcam, USA), the Human IL-6 ELISA Kit (Abcam, USA), the Mouse TNF alpha ELISA Kit (Abcam, USA), or the Human TNF alpha ELISA Kit (Abcam, USA) according to the manufacture's instruction.

2.8 Cell viability assay

After treatments, cell viability of macrophages was detected by the Cell Counting Kit-8 (Beyotime, China) according to the manufacture's instruction.

2.9 Cell apoptosis assay

Cell apoptosis was measured using the TUNNEL staining kit (Beyotime, China) according to the manufacturer’s instructions.

2.10 Cell-Cycle analysis
The trypsinized cells (1×10^6) were fixed with 75% ethanol at 4°C for 24 h. The fixed cells were incubated with RNase A (for 30 min at 374°C) after being washed with PBS, and 5 mL of PI (Beyotime, China) was added to the cell suspension. The mixture was incubated at room temperature for 30 min in the dark. The suspended cells were analyzed for cell cycle using flow cytometry (FACSCelesta 2, BD Biosciences). The percentages of cells in the G0/G1, S, and G2/M phases were counted and compared.

### 2.11 Cell senescence analysis

Cell senescence was measured using the Fluorescein di-beta-D-galactopyranoside kit (Biolite, China) by fluorescence microscope according to the manufacturer's instructions.

### 2.12 RNA immunoprecipitation (RIP)

RIP assay was performed with Magna RIP Kit (Millipore, USA) following the manufacturer's instructions. In brief, magnetic beads were mixed with 5 μg anti-m6A antibody (Abcam, USA), anti-Mettl3 antibody (Abcam, USA), anti-flag antibody (Abcam, USA), or anti-mouse/rabbit IgG (Abcam, USA) before the addition of cell lysates (approximately 2*10^7 cells for each sample). After the treatment of proteinase K, interested RNAs were eluted from immunoprecipitated complex and purified for further analysis using qPCR. Immunoprecipitated RNA was analyzed through qRT-PCR.

### 2.13 Co-Immunoprecipitation (Co-IP)

Co-IP assay was performed using Dynabeads™ Co-Immunoprecipitation Kit (ThermoFisher USA), according to the manufacturer's instruction. Briefly, the protein extracted with IP Lysis Buffer was subject to beads premixed with anti-Mettl3 antibody (Abcam, USA) or IgG. The immunoprecipitated protein complex was separated from beads after several washes, followed by the identification for partners of Mettl3 by immunoblots.

### 2.14 Chromatin immunoprecipitation (ChIP) assay

ChIP assay was performed with Magna ChIP™ A/G kit (Millipore, USA) according to manufacturer's instruction. In brief, 10^7 cells fixed with formaldehyde were collected and subject to 500 ul lysis buffer. Then lysate was sonicated, and then the supernatant was diluted and fully mixed with Protein A/G magnetic beads. Then 5 μg of anti-Mettl3 antibody (Abcam, USA), anti-STAT1 antibody (Abcam, USA), or IgG was added in respectively, followed by incubation at 4 °C overnight. The next day, after washing, the mixture was incubated with elution buffer at 62 °C for 2 h and then at 95 °C for 10 min. Then DNA was purified from the elution and was subject to RT-qPCR with primers: IL-6 promoter (forward: 5′-GTTCTGTTTTTCTGCCCACCT-3′; reverse: 5′-ATGTACACTAAGTCCACCATG-3′). Relative enrichment was normalized to the input: %Input =1/10 × 2^{Ct [IP] – Ct [input]}.

### 2.15 Statistical analysis
Data were analyzed using SPSS version 19.0 and presented as means ± standard deviation (SD). Student’s t-test was performed to analyze differences between the two groups and ANOVA (parametric) was performed to analyze differences among multiply groups. P < 0.05 was considered to indicate statistical significance.

3. Results

3.1 oxLDL stimulation significantly increases m6A modification levels in macrophages and knockdown of Mettl3 inhibits oxLDL-induced m6A modification and inflammatory response

Recent study reports that an aberrant m6A level exists in different stages of atherosclerotic lesions [19]. To explore whether m6A modification is involved in oxLDL-induced inflammatory response in macrophages, we first examined the global m6A levels in oxLDL-stimulated macrophages. As shown in Fig. 1A, oxLDL stimulation significantly promotes m6A modification level of RNA in macrophages. We further examined the expression levels of m6A “writers”, and found that oxLDL stimulation evidently increased the mRNA and protein expression levels of Mettl3 and LOX-1 but not Mettl14, WTAP or other m6A modification-related proteins (Fig. 1B, 1C and supplementary Fig. 1A, 1B, 1C). Moreover, we examined the effects of Mettl3 on the global m6A levels and inflammatory response in oxLDL-stimulated macrophages, and found that Mettl3 knockdown significantly suppressed oxLDL-induced upregulation of global m6A levels (Fig. 1D and 1E) and inhibited oxLDL-induced expressions of pro-inflammatory factors, IL-6 and TNF-α (Fig. 1F). Collectively, the results suggest that oxLDL stimulation significantly promotes m6A modification level of RNA in macrophages and knockdown of Mettl3 inhibits oxLDL-induced m6A modification and inflammatory response.

3.2 Mettl3 promoting oxLDL-induced inflammatory response in macrophages depends on its methyltransferase activity

M6A modification of mRNA is related to regulation of gene expression [21]. qRT-PCR analysis showed that oxLDL treatment significantly increased IL-6 or TNF-α mRNA expression in macrophages (Fig. 2A). To further explore the underlying mechanism of Mettl3 promoting oxLDL-induced pro-inflammatory factor expression in macrophages, we examined whether Mettl3 affected m6A modification on pro-inflammatory factor, IL-6 and TNF-α mRNA by RIP assay. The results showed that oxLDL stimulation did not affect m6A modification or Mettl3 binding to IL-6/TNF-α mRNA (Fig. 2B and 2C). Furthermore, Mettl3 knockdown did not affect m6A modification on IL-6/TNF-α mRNA (Fig. 2D). Besides, Mettl3 did not affect cell viability, cell apoptosis, cell cycle, or cell senescence (Supplementary Fig. 1F, 1G, 1H and 1I). In consideration of that the methyltransferase activity of Mettl3 is essential for regulating gene expression [20], we further examined whether the methyltransferase activity of Mettl3 affected IL-6/TNF-α mRNA. Next, we constructed a series of truncated mutants of Mettl3, including M3d (which has the mutation of C to S at the position of 314 amino acid, resulting in nearly abolishing the methyltransferase activity [21]), ΔN (which encompasses residues 259 to 580), and ΔNd (which has the mutation of C to S at the position of 314 amino acid in ΔN mutant) (Fig. 2E). qRT-PCR analysis showed that overexpression of Mettl3 or
Mettl3 ΔN mutant significantly promoted IL-6/TNF-α mRNA expression, whereas overexpression of Mettl3 M3d or Mettl3 ΔNd mutant did not obviously affect IL-6/TNF-α mRNA expression (Fig. 2F). In addition, overexpression of Mettl3 or Mettl3 M3d did not affect cell viability or apoptosis (supplementary Fig. 1D and 1E). Collectively, the results suggest that Mettl3 promoting oxLDL-induced inflammatory response in macrophages depends on its methyltransferase activity.

3.3 Mettl3 promotes oxLDL-induced inflammatory response in macrophages through regulating STAT1

Considering that inflammatory response is usually triggered by mitogen-activated protein kinase (MAPK) signaling, such as p38 and Jun-NH(2)-terminal kinase (JNK), p65 nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling, and Janus kinase (JAK)-signal transducer and activator of transcription 1/3(STAT1/3) signaling [22-26], we further explored whether Mettl3 promoting oxLDL-induced inflammatory response in macrophages is associated with these signaling pathways. As shown in Fig. 3A, oxLDL stimulation significantly promoted the protein expressions of phosphorylated p38 (p-p38), p-JNK1/2, p-p65, p-STAT1, and p-STAT3, but Mettl3 knockdown obviously suppressed the upregulation of total STAT1 and p-STAT1 protein expressions. Furthermore, we found that oxLDL stimulation significantly increased m6A modification of STAT1 mRNA (Fig. 3C). Moreover, knockdown of STAT1 not only obviously inhibited oxLDL-induced IL-6/TNF-α mRNA expression in macrophages, but also suppressed Mettl3 overexpression-induced IL-6/TNF-α mRNA expression (Fig. 3D and 3E). Overall, the results indicate that Mettl3 promotes oxLDL-induced inflammatory response in macrophages through regulating STAT1.

3.4 oxLDL stimulation significantly promoted m6A modification of STAT1 mRNA, and enhanced Mettl3 interacting with STAT1 mRNA

Considering that knockdown of Mettl3 inhibits oxLDL-induced activation of STAT1 (Fig. 3A) and Mettl3 has recently been reported to methylate STAT1 mRNA [27], we further explore whether Mettl3 affecting STAT1 activation is associated with its methyltransferase activity. As shown in Fig. 4A and 4B, overexpression of Mettl3 or Mettl3 ΔN mutant significantly promoted STAT1 mRNA expression and interacted with STAT1 mRNA, whereas overexpression of Mettl3 M3d or Mettl3 ΔNd mutant did not obviously effect, suggesting that the methyltransferase activity of Mettl3 is essential for Mettl3 promoting STAT1 expression. Furthermore, we found that oxLDL stimulation significantly promoted m6A modification of STAT1 mRNA, and enhanced Mettl3 interacting with STAT1 mRNA (Fig. 4C and 4D). Moreover, we found that knockdown of Mettl3 obviously inhibited m6A modification level of STAT1 mRNA under normal or oxLDL-stimulated condition (Fig. 4E). Overall, the results indicate that Mettl3 promotes STAT1 mRNA expression through regulating m6A modification of STAT1 mRNA.

3.5 Mettl3 interacts with STAT1 to promote STAT1 transcriptional regulation of inflammatory factor expression
Considering that STAT1 is a well-known master transcription factor controlling expressions of inflammatory factors, such as IL-6 and TNF-α [28, 29], we further explore whether Mettl3 also affects the transcriptional binding of STAT1. The results of Co-IP showed that Mettl3 interacted with STAT1 in macrophages under normal condition, and oxLDL stimulation further increased the interaction of Mettl3 and STAT1 (Fig. 5A and 5B). Furthermore, we found that oxLDL stimulation significantly promoted STAT1 and Mettl3 binding to IL-6 gene promoter through ChIP analysis (Fig. 5C and 5D). Moreover, knockdown of Mettl3 obviously decreased STAT1 binding to IL-6 gene promoter (Fig. 5E), and knockdown of STAT1 also significantly decreased Mettl3 binding to IL-6 gene promoter (Fig. 5F), suggesting that the Mettl3-STAT1 complex is essential for transcriptional regulation of STAT1. Overall, the results indicate that Mettl3 interacts with STAT1 to promote STAT1 transcriptional regulation of inflammatory factor expression.

### 3.6 Mettl3 interacts with STAT1 to promote inflammatory factor expression in monocytes from patients with angiographically proven coronary artery disease (CAD)

To further explore the relationship between m6A modification and inflammatory response in AS, we collected blood samples of patients with angiographically proven CAD and healthy donors in clinical, and then detected the m6A modification changes in monocytes. As shown in Fig. 6A and 6B, m6A modification levels of RNA in monocytes from patients with CAD were evidently higher than those in healthy donors, and Mettl3 protein levels were indeed higher than those in healthy donors, which are consistent with the results of Fig. 1A and 1C. Furthermore, we found that expressions of pro-inflammatory factors, IL-6 and TNF-α from monocytes of patients with CAD were also significantly higher than those from healthy donors, and knockdown of Mettl3 (Fig. 6C) evidently inhibited IL-6 and TNF-α expressions (Fig. 6D). Moreover, Co-IP analysis showed that Mettl3 could immunoprecipitate more STAT1 protein in monocytes from patients with CAD than that in healthy donors (Fig. 6E). In addition, Chip analysis showed that more Mettl3 and STAT1 protein bound IL-6 gene promoter in monocytes from patients with CAD, compared to those in healthy donors (Fig. 6F and G). Overall, these results indicate Mettl3 interacts with STAT1 to promote inflammatory factor expression in monocytes from patients with angiographically proven coronary artery disease.

### 4. Discussion

AS is now generally considered as a chronic inflammatory disorder with the interaction between inflammation and lipids as a major hallmark [6]. Macrophages, as the most abundant immune cell type in atherosclerotic lesions, play essential role during all stages of the disease [7]. Recent study reports m6A modification levels of RNA are differentially regulated in atherosclerotic lesions [18]. In this study, our group firstly explored the role of Mettl3 in oxLDL-induced inflammation in macrophages and detected the m6A modification level in monocytes from patients with CAD. By performing RIP and Co-IP experiments, we demonstrate that Mettl3 promotes oxLDL-induced IL-6 and TNF-α transcription by upregulating STAT1 protein expression and interacting with STAT1 to activate target genes transcription. Our study clarifies the methyltransferase activity and the non-methyltransferase activity of Mettl3 are involved in STAT3
regulating transcriptional activation during oxLDL-induced inflammatory responses. As is known, m6A modifications on mRNA was induced by Mettl3-Mettl4-Wtap complex [30], but in our study only Mettl3 was obviously upregulated by oxLDL treatment. Although Mettl4 and Wtap were not significantly changed under oxLDL stimulation in macrophages, they should also participate in Mettl3-mediated m6A modifications on STAT1 mRNA. Why only Mettl3, but not other complex components, was regulated by oxLDL? We thought this phenomenon maybe contributes to that Mettl3 also participates in oxLDL-induced biological activities, which is independent on its methyltransferase activity. Mettl3-mediated m6A modifications on STAT1 mRNA promotes STAT1 protein expression in macrophages. Whether this effect dependent on “m6A readers” such as YTHDF1/2/3 [31-33] or IGF2BP1/2/3 [34-36] is also unknown. In this study, we find that Mettl3 cooperates with STAT1 to promote its transcriptional activity. Since m6A modifications on nascent mRNA mediated by Mettl3 could form DNA/RNA hybrid with local single-strand DNA, and DNA/RNA hybrid generally hinders gene transcription [37]. We hypothesized how Mettl3 coordinates with DNA/RNA hybrid formation and interacting with STAT1, whether STAT1 interacting with Mettl3 affects its methyltransferase activity. All these details need to be investigated further. Overall, we firstly explored the role of Mettl3 during oxLDL-induced inflammation in macrophages and in monocytes from patients with CAD, and found the Mettl3-STAT1 axis was essential for inflammatory factors transcription.

Conclusion

oxLDL stimulation significantly promoted m6A modification level of mRNA and Mettl3 expression in macrophages, and knockdown of Mettl3 inhibitd oxLDL-induced m6A modification and inflammatory response. In mechanism, Mettl3 enhances oxLDL-triggered inflammation through promoting STAT1 expression in a m6A-dependent manner, and Mettl3 interacts with STAT1 to promote STAT1 transcriptional regulation of inflammatory factor expression in RAW264.7 macrophages, which was also demonstrated in the monocytes from patients with angiographically proven coronary artery disease, suggesting that Mettl3 may be as a potential target for the clinical treatment of atherosclerosis.

Declarations

Ethics approval and consent to participate:

The present study was granted an exemption from requiring ethics approval by Zhejiang University because it did not involve human subjects.

Competing interests:

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Acknowledgments:
Consent for publication

Written informed consent was obtained from all subjects before the study.

Availability of data and materials

The data used to support the findings of this study are available from the corresponding author upon request.

Funding:

The study was supported by Zhejiang Provincial Natural Science Foundation of China (Grant No.LY19H020003, LY19H310002), Ningbo Health Branding Subject Fund (Grant No.PPXK2018-01).

Authors' contributions:

Jianhua Zhu and Xiaomin Chen designed the study, Zhenwei Li performed the research, Qingqing Xu analysed data, Zhenwei Li and Huangfu Ning wrote the paper.

References

[1] E. Pardali, S. Dimmeler, A.M. Zeiher, M.A. Rieger: Clonal hematopoiesis, aging, and cardiovascular diseases. Exp Hematol 83:95-104, 2020.

[2] E.J. Benjamin, S.S. Virani, C.W. Callaway, A.M. Chamberlain, A.R. Chang, S. Cheng, et al: Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation 137: e67-e492, 2018.

[3] J.O. Fajemiroye, L.C. da Cunha, R. Saavedra-Rodriguez, K.L. Rodrigues, L.M. Naves, A.A. Mourao, et al: Aging-Induced Biological Changes and Cardiovascular Diseases. Biomed Res Int 2018: 7156435, 2018.

[4] P.K. Shah, Inflammation, infection and atherosclerosis: Trends Cardiovas Med 29: 468-472, 2019.

[5] G. Siasos: The Role of Endothelium in Cardiovascular Diseases. New Insights, Curr Med Chem 27: 1019-1020, 2020.

[6] T.J. Barrett: Macrophages in Atherosclerosis Regression. Arterioscl Throm Vas 40: 20-33, 2020.

[7] H. Xu, J. Jiang, W. Chen, W. Li, Z. Chen: Vascular Macrophages in Atherosclerosis. J Immunol Res 2019: 4354786, 2019.
[8] G.J. Koelwyn, E.M. Corr, E. Erbay, K.J. Moore: Regulation of macrophage immunometabolism in atherosclerosis. Nat Immunol 19: 526-537, 2018.

[9] D.A. Chistiakov, A.A. Melnichenko, V.A. Myasoedova, A.V. Grechko, A.N. Orekhov: Mechanisms of foam cell formation in atherosclerosis. J Mol Med 95: 1153-1165, 2017.

[10] B. Herrero-Fernandez, R. Gomez-Bris, B. Somovilla-Crespo, J.M. Gonzalez-Granado: Immunobiology of Atherosclerosis: A Complex Net of Interactions. Int J Mol Sci 20, 2019.

[11] Krzysztof Sikorski, Anna Czerwoniec, Janusz M, Bujnicki, Joanna Wesoly, Hans A.R, Bluyssen: STAT1 as a novel therapeutic target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease. Cytokine Growth F R 22:211-219,2011.

[12] X.Y. Chen, J. Zhang, J.S. Zhu: The role of m(6)A RNA methylation in human cancer. Mol Cancer 18: 103, 2019.

[13] T. Sun, R. Wu, L. Ming: The role of m6A RNA methylation in cancer. Biomed Pharmacother 112: 108613, 2019.

[14] G. Cao, H.B. Li, Z. Yin, R.A. Flavell: Recent advances in dynamic m6A RNA modification. Open biol 6: 160003, 2016.

[15] J. Chen, C. Wang, W. Fei, X. Fang, X. Hu: Epitranscriptomic m6A modification in the stem cell field and its effects on cell death and survival. Am J Cancer Res 9: 752-764, 2019.

[16] J. Li, L. Zhu, Y. Shi, J. Liu, L. Lin, X. Chen: m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation. Am J Transl Res 11: 6084-6092, 2019.

[17] T. Liu, Q. Wei, J. Jin, Q. Luo, Y. Liu, Y. Yang, C. et al: The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res 48: 3816-3831, 2020.

[18] Y. Gao, G. Pei, D. Li, R. Li, Y. Shao, Q.C. Zhang, et al: Multivalent m(6)A motifs promote phase separation of YTHDF proteins. Cell Res 29: 767-769, 2019.

[19] A. Quiles-Jimenez, I. Gregersen, M. Mittelstedt Leal de Sousa, A. Abbas, X.Y. Kong, I. Alseth, et al: N6-methyladenosine in RNA of atherosclerotic plaques: An epitranscriptomic signature of human carotid atherosclerosis. Biochem Bioph Res Co, 2020.

[20] D. Jian, Y. Wang, L. Jian, H. Tang, L. Rao, K. Chen, et al: METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOX01 N6-methyladenosine modifications. Theranostics 10: 8939-8956, 2020.

[21] J. Huang, X. Dong, Z. Gong, L.Y. Qin, S. Yang, Y.L. Zhu, et al: Solution structure of the RNA recognition domain of METTL3-METTL14 N(6)-methyladenosine methyltransferase. Protein & cell 10:
[22] H. Song, X. Feng, H. Zhang, Y. Luo, J. Huang, M. Lin, et al: METTL3 and ALKBH5 oppositely regulate m(6)A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes. Autophagy 15: 1419-1437, 2019.

[23] Y. Kuang, H. Liu, S. Guo, Y. Wang, H. Zhang, Y. Qiao: The antagonist of P2Y11 receptor NF157 ameliorates oxidized LDL-induced vascular endothelial inflammation. Artif Cell Nanomed B 47: 1839-1845, 2019.

[24] J. Cheriyan, A.J. Webb, L. Sarov-Blat, M. Elkhawad, S.M. Wallace, K.M. Maki-Petaja, et al: Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 123: 515-523, 2011.

[25] B. Soltani, N. Bodaghabadi, N. Ghaemi, M. Sadeghizadeh: Radiation-induced surge of macrophage foam cell formation, oxidative damage, and cytokine release is attenuated by a nanoformulation of curcumin. Int J Radiat Biol 93: 303-314, 2017.

[26] L. Jiang, X.Q. Chen, M.J. Gao, W. Lee, J. Zhou, Y.F. Zhao, et al: The Pros1/Tyro3 axis protects against periodontitis by modulating STAT/SOCS signalling. J Cell Mol Med 23: 2769-2781, 2019.

[27] H. Dokduang, A. Techasen, N. Namwat, N. Khuntikeo, C. Pairojkul, Y. Murakami, et al: STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression. J Hepato-Bil-Pan Sci 21: 767-776, 2014.

[28] Y. Liu, Z. Liu, H. Tang, Y. Shen, Z. Gong, N. Xie, et al: The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 facilitates M1 macrophage polarization through the methylation of STAT1 mRNA, Am J Physiol-Cell Ph 317: C762-C775, 2019.

[29] K. Hirahara, A. Onodera, A.V. Villarino, M. Bonelli, G. Sciume, A. Laurence, et al: Asymmetric Action of STAT Transcription Factors Drives Transcriptional Outputs and Cytokine Specificity. Immunity 42: 877-889, 2015.

[30] X. Cheng, Y. Liu, H. Chu, H.Y. Kao: Promyelocytic leukemia protein (PML) regulates endothelial cell network formation and migration in response to tumor necrosis factor alpha (TNFalpha) and interferon alpha (IFNalpha). J Biol Inorg Chem 287: 23356-23367, 2012.

[31] M. Scarrow, N. Chen, G. Sun: Insights into the N(6)-methyladenosine mechanism and its functionality: progress and questions. Crit Rev Biotechnol 40: 639-652, 2020.

[32] X. Wang, B.S. Zhao, I.A. Roundtree, Z. Lu, D. Han, H. Ma, et al: N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell 161: 1388-1399, 2015.
[33] J. Chen, Y. Sun, X. Xu, D. Wang, J. He, H. Zhou, et al: YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells. Cell cycle 16: 2259-2271, 2017.

[34] T. Ghazi, S. Nagiah, A.A. Chuturgoon: Fusaric acid decreases p53 expression by altering promoter methylation and m6A RNA methylation in human hepatocellular carcinoma (HepG2) cells. Epigenetics: 1-13, 2020.

[35] Z. Wang, X. Zhang, E. Jiang, H. Yan, H. Zhu, H. Chen, et al: InDels within caprine IGF2BP1 intron 2 and the 3'-untranslated regions are associated with goat growth traits. Anim Genet 51: 117-121, 2020.

[36] X. Liu, P. Wu, R. Su, Y. Xue, C. Yang, D. Wang, et al: IGF2BP2 stabilized FBXL19-AS1 regulates the blood-tumour barrier permeability by negatively regulating ZNF765 by STAU1-mediated mRNA decay. RNA bio:1-12, 2020.

[37] Y.M. Shaalan, H. Handoussa, R.A. Youness, R.A. Assal, A.H. El-Khatib, M.W. Linscheid, et al: Destabilizing the interplay between miR-1275 and IGF2BPs by Tamarix articulata and quercetin in hepatocellular carcinoma. Nat Prod Res 32: 2217-2220, 2018.

[38] S. Kaiser, T.P. Jurkowski, S. Kellner, D. Schneider, A. Jeltsch, M. Helm: The RNA methyltransferase Dnmt2 methylates DNA in the structural context of a tRNA. RNA biology 14: 1241-1251, 2017.

**Figures**
oxLDL stimulation significantly promotes m6A modification level of RNA in macrophages and knockdown of mettl3 inhibits oxLDL-induced m6A modification and inflammatory response. (A) Dot blot quantification of m6A abundance in the mRNA isolated from the RAW264.7 macrophage cells treated with 40 μg/ml oxLDL or not for 24 h. (B) qRT-PCR analysis of the indicated genes in RAW264.7 cells treated with oxLDL or not for 24 h. (C) WB analysis of the indicated proteins in RAW264.7 cells treated with oxLDL or not for 24 h. (D) WB analysis of the effect of siRNA-Mettl3 (si-M3). NC is the negative control. (E) Dot blot quantification of m6A abundance in the mRNA isolated from the RAW264.7 macrophage cells transfected with si-M3 and treated with oxLDL. (F) Elisa analysis of the protein expression levels of IL-6 or TNF-α in the cell culture supernatants from the RAW264.7 macrophage cells transfected with si-M3 and treated with oxLDL. Data are represented as means ± SD (n=3; *represents P < 0.05).
Figure 2

Mettl3 promoting oxLDL-induced inflammatory response in macrophages depends on its methyltransferase activity. (A) qRT-PCR analysis of IL-6 or TNF-α mRNA expression in RAW264.7 cells treated with different density oxLDL (B) RIP analysis of the m6A modification level on IL-6 or TNF-α mRNA in RAW264.7 cells treated with oxLDL or not for 24 h. (C) RIP analysis of Mettl3 (M3) interacting with IL-6 or TNF-α mRNA in RAW264.7 cells treated with oxLDL or not for 24 h. (D) RIP analysis of the m6A modification level on IL-6 or TNF-α mRNA in RAW264.7 macrophage cells transfected with si-M3 and treated with oxLDL, (E) WB analysis of protein expressions in RAW264.7 cells transfected with different truncated mutants of flag-labelled Mettl3. M3, wild type Mettl3 containing 1 to 580 amino acid; M3d has the mutation of C to S at the position of 314 amino acid, resulting in nearly abolishing the methyltransferase activity; ΔN encompasses residues 259 to 580; ΔNd has the mutation of C to S at the position of 314 amino acid in ΔN mutant. (F) qRT-PCR analysis of IL-6 or TNF-α mRNA expression in RAW264.7 cells transfected with different truncated mutants of flag-labelled Mettl3. Data are represented as means ± SD (n=3; *represents P < 0.05).
Mettl3 promotes oxLDL-induced inflammatory response in macrophages through regulating STAT1. (A) WB analysis of the indicated protein expressions in RAW264.7 cells transfected with transfected with si-M3 and treated with oxLDL. (B) RIP analysis of Mettl3 (M3) interacting with STAT1 mRNA in RAW264.7 cells treated with oxLDL or not. (C) WB analysis of the effect of siRNA-STAT1 (si-ST1). NC is the negative control. (D) qRT-PCR analysis of IL-6 or TNF-α mRNA expression in RAW264.7 cells transfected with si-ST1 and treated with oxLDL. (E) qRT-PCR analysis of IL-6 or TNF-α mRNA expression in RAW264.7 cells transfected with si-ST1 and pCMV-flag-Mettl3 (M3). Data are represented as means ± SD (n=3; *represents P < 0.05).
oxLDL stimulation significantly promoted m6A modification of STAT1 mRNA, and enhanced Mettl3 interacting with STAT1 mRNA. (A) WB analysis of protein expressions in RAW264.7 cells transfected with different truncated mutants of flag-labelled Mettl3 (Left). qRT-PCR analysis of STAT1 mRNA expression in RAW264.7 cells transfected with different truncated mutants of flag-labelled Mettl3 (Right). (B) RIP analysis of different truncated mutants of flag-labelled Mettl3 interacting with STAT1 mRNA in RAW264.7 cells. (C) RIP analysis of the m6A modification level on STAT1 mRNA in RAW264.7 cells treated with oxLDL or not for 24 h. (D) RIP analysis of Mettl3 (M3) interacting with STAT1 mRNA in RAW264.7 cells treated with oxLDL or not. (E) RIP analysis of the m6A modification level on STAT1 mRNA in RAW264.7 cells transfected with si-ST1 and treated with oxLDL. Data are represented as means ± SD (n=3; *represents P < 0.05).
Figure 5

Mettl3 interacts with STAT1 to promote STAT1 transcriptional regulation of inflammatory factor expression. (A) Co-IP analysis of Mettl3 interacting with STAT1 in RAW264.7 cells. (B) Co-IP analysis of Mettl3 interacting with STAT1 in RAW264.7 cells treated with oxLDL or not. (C) Chip analysis of STAT1 interacting with IL-6 gene promoter region in RAW264.7 cells treated with oxLDL. (D) Chip analysis of Mettl3 interacting with IL-6 gene promoter region in RAW264.7 cells treated with oxLDL. (E) Chip analysis of STAT1 interacting with IL-6 gene promoter region in RAW264.7 cells transfected with si-M3 and treated with oxLDL. (F) Chip analysis of Mettl3 interacting with IL-6 gene promoter region in RAW264.7 cells transfected with si-ST1 and treated with oxLDL. Data are represented as means ± SD (n=3; *represents P < 0.05).
Figure 6

Mettl3 interacts with STAT1 to promote inflammatory factor expression in monocytes from patients with angiographically proven coronary artery disease (CAD). (A) Dot blot quantification of m6A abundance in the mRNA isolated from the monocytes from patients with CAD (n=16) or healthy donors (n=8). (B) WB analysis of Mettl3 protein expression in monocytes from patients with CAD (n=6) or healthy donors (n=6). (C) qRT-PCR analysis of Mettl3 genes in PBMCs transfected with si-nc or si-Mettl3 (si-M3) for 24 h. (D) Elisa analysis of the protein expression levels of IL-6 or TNF-α in the cell culture supernatants of monocytes from patients with CAD or healthy donors transfected with si-M3. (E) Co-IP analysis of Mettl3 interacting with STAT1 in monocytes from patients with CAD or healthy donors. (F) Chip analysis of Mettl3 interacting with IL-6 gene promoter region in monocytes from patients with CAD or healthy donors. (G) Chip analysis of STAT1 interacting with IL-6 gene promoter region in monocytes from patients with CAD or healthy donors. Data are represented as means ± SD (n=3; *represents P < 0.05).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.
• supplementalfigure1.tif